Breaking News, Trials & Filings

Trials & Filings in Brief: Sept. 26, 2013

Dompe, Exelixis, Lilly, Lumena, NovaRx, ProMetic, Sarepta,

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Preclinical ProMetic’s fibrosis candidate safe for trials . . . read more Phase II Positive results for Sarepta in DMD extension . . . read more Lumena tests LUM001 in rare liver disease in children . . . read more Phase II/III Dompe to test Reparixin in autologous islet cell transplantation . . . read more Phase III Mixed results for Lilly . . . read more Lucanix results miss endpoint in NSCLC . . . read more Exelixis completes enrollment in mCRPC trial . . . read more...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters